MEDICAMEQ Stock Overview
A pharmaceutical company, research, develops, manufactures, markets, sells, and distributes pharmaceutical formulations in India and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 1/6 |
| Financial Health | 3/6 |
| Dividends | 1/6 |
Medicamen Biotech Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₹446.75 |
| 52 Week High | ₹645.85 |
| 52 Week Low | ₹355.45 |
| Beta | 1.5 |
| 11 Month Change | -10.36% |
| 3 Month Change | 9.35% |
| 1 Year Change | -29.92% |
| 33 Year Change | -25.42% |
| 5 Year Change | n/a |
| Change since IPO | -19.07% |
Recent News & Updates
Medicamen Biotech Limited's (NSE:MEDICAMEQ) P/S Is Still On The Mark Following 41% Share Price Bounce
Sep 28
Medicamen Biotech (NSE:MEDICAMEQ) Will Pay A Dividend Of ₹1.00
Sep 03Medicamen Biotech (NSE:MEDICAMEQ) Is Due To Pay A Dividend Of ₹1.00
Aug 16Recent updates
Medicamen Biotech Limited's (NSE:MEDICAMEQ) P/S Is Still On The Mark Following 41% Share Price Bounce
Sep 28Medicamen Biotech (NSE:MEDICAMEQ) Will Pay A Dividend Of ₹1.00
Sep 03Medicamen Biotech (NSE:MEDICAMEQ) Is Due To Pay A Dividend Of ₹1.00
Aug 16These 4 Measures Indicate That Medicamen Biotech (NSE:MEDICAMEQ) Is Using Debt Extensively
Jul 04What Medicamen Biotech Limited's (NSE:MEDICAMEQ) 28% Share Price Gain Is Not Telling You
May 21More Unpleasant Surprises Could Be In Store For Medicamen Biotech Limited's (NSE:MEDICAMEQ) Shares After Tumbling 26%
Mar 17Medicamen Biotech (NSE:MEDICAMEQ) Will Pay A Dividend Of ₹1.00
Sep 13Why Medicamen Biotech's (NSE:MEDICAMEQ) Shaky Earnings Are Just The Beginning Of Its Problems
Nov 19There's Reason For Concern Over Medicamen Biotech Limited's (NSE:MEDICAMEQ) Price
Dec 03Shareholder Returns
| MEDICAMEQ | IN Pharmaceuticals | IN Market | |
|---|---|---|---|
| 7D | -2.7% | -0.5% | -1.2% |
| 1Y | -29.9% | 41.6% | 25.5% |
Return vs Industry: MEDICAMEQ underperformed the Indian Pharmaceuticals industry which returned 41.6% over the past year.
Return vs Market: MEDICAMEQ underperformed the Indian Market which returned 25.5% over the past year.
Price Volatility
| MEDICAMEQ volatility | |
|---|---|
| MEDICAMEQ Average Weekly Movement | 8.8% |
| Pharmaceuticals Industry Average Movement | 6.0% |
| Market Average Movement | 6.1% |
| 10% most volatile stocks in IN Market | 9.1% |
| 10% least volatile stocks in IN Market | 4.0% |
Stable Share Price: MEDICAMEQ's share price has been volatile over the past 3 months compared to the Indian market.
Volatility Over Time: MEDICAMEQ's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of Indian stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1993 | 378 | Rajesh Madan | www.medicamen.com |
Medicamen Biotech Limited, a pharmaceutical company, research, develops, manufactures, markets, sells, and distributes pharmaceutical formulations in India and internationally. The company offers drugs in various forms, including tablet, capsule, oral solution, and drops. Its products are used in therapeutic areas comprising cancer care, cardiology, CNS, diabetology, anti-infective, anti-malarial, vitamins and supplements, other generics, and pain management.
Medicamen Biotech Limited Fundamentals Summary
| MEDICAMEQ fundamental statistics | |
|---|---|
| Market cap | ₹5.70b |
| Earnings (TTM) | ₹81.05m |
| Revenue (TTM) | ₹1.80b |
70.3x
P/E Ratio3.2x
P/S RatioIs MEDICAMEQ overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| MEDICAMEQ income statement (TTM) | |
|---|---|
| Revenue | ₹1.80b |
| Cost of Revenue | ₹958.22m |
| Gross Profit | ₹845.89m |
| Other Expenses | ₹764.84m |
| Earnings | ₹81.05m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 6.37 |
| Gross Margin | 46.89% |
| Net Profit Margin | 4.49% |
| Debt/Equity Ratio | 15.4% |
How did MEDICAMEQ perform over the long term?
See historical performance and comparison